Related Experiment Videos
Aromatase inhibitors and their use in the sequential setting
R C Coombes1, C Harper-Wynne, M Dowsett
1Cancer Research Campaign, Department of Cancer Medicine, Imperial College School of Medicine, Charing Cross Hospital, London, UK.
Endocrine-Related Cancer
|March 24, 2000
Summary
Novel aromatase inhibitors, including third-generation drugs like anastrozole and letrozole, offer improved efficacy in reducing oestradiol levels. Sequential use may enhance remission duration for hormone receptor-positive tumors.
Area of Science:
- Endocrinology
- Oncology
- Pharmacology
Background:
- Aromatase inhibitors reduce oestradiol levels, crucial for treating hormone-sensitive cancers.
- Aminogluthemide's mechanism revealed aromatase as a therapeutic target.
- Evolution from first-generation to more potent third-generation inhibitors.
Purpose of the Study:
- To review the development and clinical application of novel aromatase inhibitors.
- To compare the efficacy of different generations of aromatase inhibitors.
- To explore the potential benefits of sequential therapy with aromatase inhibitors.
Main Methods:
- Literature review of aromatase inhibitor development and clinical studies.
- Comparison of efficacy based on reported aromatase inhibition percentages.
- Discussion of sequential treatment strategies in clinical practice.
Main Results:
- Third-generation inhibitors (anastrozole, letrozole, vorozole, exemestane) inhibit aromatase >95%, surpassing older agents.
- Formestane (second-generation) demonstrated good tolerability but required parenteral administration.
- Sequential administration of different aromatase inhibitor generations is under investigation.
Conclusions:
- Novel aromatase inhibitors represent significant advancements in endocrine therapy for breast cancer.
- Third-generation inhibitors offer superior efficacy in reducing oestradiol levels.
- Optimal sequencing of aromatase inhibitors may prolong remission in hormone receptor-positive tumors.